Abstract
The use of calcium channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors has increased dramatically over the last 10 years and now accounts for 60% to 70% of all new antihypertensive prescriptions. Even though these two classes are efficacious, they are costly. Combined ACE inhibitor/CCB therapy (amlodipine-benazepril) was introduced in 1995. An analysis was done to assess the potential financial impact of substituting this agent for patients being treated with on ACE inhibitor/CCB combination. A pharmaceutical profile review of prescriptions during October 1995 was performed on 219 randomly selected patients enrolled in a Medicaid managed care program. Eighty-four profiles were analyzed; 24% of patients were on a combination ACE inhibitor/CCB regimen with an average monthly cost of $135. If the single agent amlodipine-benazepril with an average monthly cost of $45 (all strengths) was substituted, the savings would be considerable: $1080 per patient per year and $1,080,000 annualized for the calculated number of hypertensives on combination therapy in our network of 15,000 patients. Therapeutic substitution is one method of achieving cost containment in managed care. The cost differential between separately prescribed CCBs and ACE inhibitors and amlodipine-benazepril is significant. Compliance also should be enhanced as the patient would need to take only one pill daily. Once a patient has been maintained on a stable dose of a CCB/ACE inhibitor, substitution with amlodipine-benazepril should be considered.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brouwer R. M., Bolli P., Erné P., Conen D., Kiowski W., Bühler F. R. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol. 1985;7 (Suppl 1):S88–S91. doi: 10.1097/00005344-198507001-00017. [DOI] [PubMed] [Google Scholar]
- Brown S. A., Walton C. L., Crawford P., Bakris G. L. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun;43(6):1210–1218. doi: 10.1038/ki.1993.171. [DOI] [PubMed] [Google Scholar]
- Elliott W. J. The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics? Postgrad Med. 1996 Apr;99(4):241-8, 251-2. [PubMed] [Google Scholar]
- Hall W. D., Kong W. Hypertension in blacks: nonpharmacologic and pharmacologic therapy. Cardiovasc Clin. 1991;21(3):157–169. [PubMed] [Google Scholar]
- Holland O. B., von Kuhnert L., Campbell W. B., Anderson R. J. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension. 1983 Mar-Apr;5(2):235–239. doi: 10.1161/01.hyp.5.2.235. [DOI] [PubMed] [Google Scholar]
- Lonn E. M., Yusuf S., Jha P., Montague T. J., Teo K. K., Benedict C. R., Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994 Oct;90(4):2056–2069. doi: 10.1161/01.cir.90.4.2056. [DOI] [PubMed] [Google Scholar]
- Manolio T. A., Cutler J. A., Furberg C. D., Psaty B. M., Whelton P. K., Applegate W. B. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995 Apr 24;155(8):829–837. [PubMed] [Google Scholar]
- Materson B. J., Reda D. J., Cushman W. C., Massie B. M., Freis E. D., Kochar M. S., Hamburger R. J., Fye C., Lakshman R., Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993 Apr 1;328(13):914–921. doi: 10.1056/NEJM199304013281303. [DOI] [PubMed] [Google Scholar]
- Reif M. C., Carter V. L. The retail cost of antihypertensive therapy. Physician and patient as educated consumers. Am J Hypertens. 1994 Jul;7(7 Pt 1):571–575. doi: 10.1093/ajh/7.7.571. [DOI] [PubMed] [Google Scholar]
- Saunders E., Weir M. R., Kong B. W., Hollifield J., Gray J., Vertes V., Sowers J. R., Zemel M. B., Curry C., Schoenberger J. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990 Aug;150(8):1707–1713. [PubMed] [Google Scholar]
- Soumerai S. B., Ross-Degnan D., Avorn J., McLaughlin T. j., Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991 Oct 10;325(15):1072–1077. doi: 10.1056/NEJM199110103251505. [DOI] [PubMed] [Google Scholar]